MENU
+Compare
ACAD
Stock ticker: NASDAQ
AS OF
Nov 21, 04:59 PM (EDT)
Price
$23.56
Change
+$0.66 (+2.88%)
Capitalization
3.98B

ACAD ACADIA Pharmaceuticals Forecast, Technical & Fundamental Analysis

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases... Show more

Industry: #Biotechnology
ACAD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ACAD with price predictions
Nov 20, 2025

ACAD in downward trend: price may drop because broke its higher Bollinger Band on November 11, 2025

ACAD broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In of the 44 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 57 cases where ACAD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on ACAD as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ACAD moved above its 50-day moving average on November 11, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ACAD crossed bullishly above the 50-day moving average on November 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 195 cases where ACAD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.344) is normal, around the industry mean (27.115). P/E Ratio (15.194) is within average values for comparable stocks, (51.613). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.036). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (3.792) is also within normal values, averaging (317.729).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ACAD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ACAD is expected to report earnings to fall 66.60% to 14 cents per share on March 02

ACADIA Pharmaceuticals ACAD Stock Earnings Reports
Q4'25
Est.
$0.14
Q3'25
Beat
by $0.28
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.13
Q4'24
Beat
by $0.64
The last earnings report on November 05 showed earnings per share of 41 cents, beating the estimate of 14 cents. With 1.35M shares outstanding, the current market capitalization sits at 3.98B.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals drugs for treatment of central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12830 El Camino Real
Phone
+1 858 558-2871
Employees
598
Web
https://www.acadia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEFX14.060.17
+1.21%
Baillie Gifford International Growth 4
RNGEX73.690.35
+0.48%
American Funds New Economy R4
CHAIX17.86N/A
N/A
Chase Growth Institutional
TASVX17.74N/A
N/A
PGIM Quant Solutions Small-Cap Val Z
MXNSX19.18N/A
N/A
Empower S&P SmallCap 600® Index L

ACAD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with STTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+2.84%
STTK - ACAD
39%
Loosely correlated
+5.18%
AURA - ACAD
39%
Loosely correlated
+1.68%
RXRX - ACAD
38%
Loosely correlated
+8.31%
VCYT - ACAD
36%
Loosely correlated
+7.74%
HRMY - ACAD
35%
Loosely correlated
+2.79%
More